{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294696","form_type":"8-K","ticker":"INTI","cik":"0001042418","company_name":"Inhibitor Therapeutics, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.001109+00:00","generated_at":"2026-06-07T12:30:18.248559+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers","bullets":["Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.","Licensed field of use: prostate cancer, basal cell carcinoma (including BCC nevus syndrome), and lung cancer.","Financial terms include upfront fee, minimum annual royalties, milestone payments, and royalties on net sales.","Company cites this as a critical milestone toward commercializing itraconazole in multiple oncology indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294696","json":"https://secwatch.observer/filing/0001193125-23-294696.json","markdown":"https://secwatch.observer/filing/0001193125-23-294696.md","text":"https://secwatch.observer/filing/0001193125-23-294696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/0001193125-23-294696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/d502337d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:30:18.248559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75e39cbef3d0b87322cdb9a33563c4afb4a6e50d","claim":"Inhibitor Therapeutics, Inc. entered into Exclusive License Agreement with Johns Hopkins University valued at License agreement including upfront license fee, minimum annual royalty payments, royalties on net s (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, Inhibitor Therapeutics, Inc. (the “Company”) entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University (“JHU”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/0001193125-23-294696-index.htm","confidence":0.97,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Johns Hopkins University"},{"label":"Value","value":"License agreement including upfront license fee, minimum annual royalty payments, royalties on net s"},{"label":"Effective","value":"2023-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}